Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a leading clinical-stage biopharmaceutical company specializing in the development of innovative therapies for immuno-inflammatory diseases. Founded by dermatologists, Aclaris leverages its extensive expertise in dermatologic treatments to address significant unmet needs in both medical and aesthetic dermatology.
Aclaris operates primarily through two segments: therapeutics and contract research. The therapeutics segment focuses on identifying and developing novel therapies to treat immuno-inflammatory diseases. Key drug candidates in this segment include Zunsemetinib, an oral MK2 inhibitor, ATI-2138, an ITJ inhibitor, and ATI-1777, a topical JAK 1/3 inhibitor. The contract research segment generates revenue by offering laboratory services, which constitute a significant portion of the company’s revenue.
Recent milestones for Aclaris include the progression of ATI-2138 into Phase 2a proof-of-concept trials for T cell-mediated autoimmune diseases and the completion of enrollment for the ATI-1777 Phase 2b trial in atopic dermatitis. Preliminary data from these trials have shown promising results, paving the way for further clinical development. Aclaris has also announced partnerships with institutions like Washington University to explore additional therapeutic applications for its drug candidates.
Financially, Aclaris maintains a robust liquidity position. As of the end of 2023, the company holds approximately $181.9 million in cash, cash equivalents, and marketable securities, ensuring the capability to fund operations through 2025. Revenue generation is primarily driven by contract research services and strategic licensing agreements, such as the recent deal with Sun Pharmaceutical Industries, Inc., which grants exclusive rights under certain patents for the use of deuruxolitinib in treating alopecia areata and androgenetic alopecia.
Aclaris Therapeutics (NASDAQ: ACRS) announced participation in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 11, 2022, at 9:00 a.m. ET. President and CEO Dr. Neal Walker and Consultant Walter Smith will discuss the company’s initiatives in developing novel drug candidates for immuno-inflammatory diseases. The chat will be accessible via Aclaris’ website and archived for 30 days. Aclaris is focused on innovative treatments for patients with unmet medical needs in immuno-inflammatory diseases.
Aclaris Therapeutics (NASDAQ: ACRS) announced its 2021 financial results, reporting a net loss of $90.9 million compared to $51.0 million in 2020. Total revenue increased to $6.8 million from $6.5 million. The company highlighted positive data from Phase 2a trials of zunsemetinib for rheumatoid arthritis and ATI-1777 for atopic dermatitis. As of December 31, 2021, Aclaris had $225.7 million in cash, sufficient to fund operations through 2024. R&D expenses rose to $43.8 million, driven by ongoing clinical trials. Aclaris aims to progress multiple drug candidates in 2022.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: ACRS), announced that Dr. Neal Walker, its President and CEO, will join a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET. Aclaris management will also be available for virtual one-on-one meetings that day. The fireside chat webcast can be accessed via the company's website and will be archived for 30 days. Aclaris focuses on developing novel treatments for immuno-inflammatory diseases, backed by a strong R&D pipeline.
Aclaris Therapeutics has appointed James Loerop as Chief Business Officer, effective January 31, 2022. Loerop brings over two decades of experience in business development, most recently serving as Executive Vice President at Anika Therapeutics. His expertise is expected to enhance Aclaris' global business development strategy for its drug pipeline targeting immuno-inflammatory diseases. Additionally, John Schindler, Ph.D., has been named Senior Director of Discovery Research, focusing on early-stage targets.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced updates on its clinical programs and R&D operations as of January 11, 2022. Two Phase 2 studies of Zunsemetinib for rheumatoid arthritis (RA) and hidradenitis suppurativa (HS) are underway, aiming to evaluate efficacy and optimal dosing. Additionally, the company has initiated a first-in-human Phase 1 trial of ATI-2138, targeting T-cell mediated autoimmune diseases. Notably, Aclaris has strengthened its R&D team and is planning to fill key leadership positions following the departure of Chief Medical Officer David Gordon.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, announced participation by Dr. Neal Walker, its President and CEO, in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference. The event will be available starting January 10, 2022, at 7:00 a.m. ET, and interested parties can access the webcast through the "Events" page on Aclaris' website. The company is focused on developing innovative drug candidates for immuno-inflammatory diseases, addressing significant unmet medical needs.
Aclaris Therapeutics (NASDAQ: ACRS) announced the publication of preclinical research on zunsemetinib in pancreatic cancer in the journal Science Translational Medicine on December 1, 2021. This study, conducted in collaboration with Washington University School of Medicine, identifies the MK2/HSP27 axis as a key survival mechanism for pancreatic cancer cells under chemotherapy stress. Results showed that zunsemetinib significantly increased mouse survival when combined with FOLFIRINOX therapy. Aclaris is considering advancing this research into clinical trials for pancreatic cancer treatment.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that the FDA has allowed its Investigational New Drug (IND) application for ATI-2138, an oral ITK/TXK/JAK3 inhibitor aimed at treating psoriasis. The company is set to provide more details on this and other drug candidates during a virtual R&D Day on December 7, 2021. Topics will include ATI-450 and ATI-2231, both MK2 inhibitors, and an Oral Gut-restricted Discovery Program. Participation in this event can be accessed via conference call or webcast from Aclaris’ website.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced participation in two upcoming investor conferences. Dr. Neal Walker, President and CEO, will engage in a virtual fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET. Additionally, he will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. Virtual one-on-one meetings will also be available. Live webcasts can be accessed via Aclaris’ website, and recordings will be archived for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported a net loss of $21.1 million for Q3 2021, compared to $10.7 million in Q3 2020, with total revenue of $1.7 million, up from $1.4 million year-over-year. R&D expenses surged to $14.0 million, influenced by efforts to advance zunsemetinib, an investigational drug for rheumatoid arthritis. The company holds $243.6 million in cash and equivalents, projected to sustain operations through 2024. Additionally, an investigational new drug application for ATI-2138 was submitted, marking potential expansion in immuno-inflammatory treatments.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
What is Aclaris Therapeutics, Inc. focused on?
What are the key drug candidates Aclaris is developing?
What recent clinical trial milestones has Aclaris achieved?
How does Aclaris generate revenue?
What was the recent licensing agreement with Sun Pharmaceutical Industries about?
What is Aclaris' financial position as of the end of 2023?
What partnerships does Aclaris have for clinical development?
What is the significance of ATI-2138's recent trial results?
What is the focus of Aclaris' therapeutics segment?
What makes Aclaris unique in the biopharmaceutical industry?
